{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:09:43Z","timestamp":1784304583775,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00198-024-07336-6","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T12:53:14Z","timestamp":1736945594000},"page":"323-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass"],"prefix":"10.1007","volume":"36","author":[{"given":"Seunghyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Joon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-5638","authenticated-orcid":false,"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"3","key":"7336_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0025-7753(01)71732-0","volume":"116","author":"M D\u00edazCuriel","year":"2001","unstructured":"D\u00edazCuriel M, Garc\u00eda JJ, Carrasco JL, Honorato J, P\u00e9rez Cano R, Rapado A, \u00c1lvarezSanz C (2001) Prevalencia de osteoporosis determinada por densitometr\u00eda en la poblaci\u00f3n femenina espa\u00f1ola. Med Clin 116(3):86\u201388. https:\/\/doi.org\/10.1016\/S0025-7753(01)71732-0","journal-title":"Med Clin"},{"key":"7336_CR2","doi-asserted-by":"publisher","unstructured":"Pepe J, Body JJ, Hadji P et al (2020) Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF. J Clin Endocrinol Metab 105(8). https:\/\/doi.org\/10.1210\/clinem\/dgaa306","DOI":"10.1210\/clinem\/dgaa306"},{"issue":"4","key":"7336_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s001980200035","volume":"13","author":"WD Hosmer","year":"2002","unstructured":"Hosmer WD, Genant HK, Browner WS (2002) Fractures before menopause: a red flag for physicians. Osteoporos Int 13(4):337\u2013341. https:\/\/doi.org\/10.1007\/s001980200035","journal-title":"Osteoporos Int"},{"issue":"1","key":"7336_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archinte.162.1.33","volume":"162","author":"F Wu","year":"2002","unstructured":"Wu F, Mason B, Horne A, Ames R, Clearwater J, Liu M, Evans MC, Gamble GD, Reid IR (2002) Fractures between the ages of 20 and 50 years increase women\u2019s risk of subsequent fractures. Arch Intern Med 162(1):33\u201336. https:\/\/doi.org\/10.1001\/archinte.162.1.33","journal-title":"Arch Intern Med"},{"issue":"3","key":"7336_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.berh.2010.01.006","volume":"24","author":"AK Bhalla","year":"2010","unstructured":"Bhalla AK (2010) Management of osteoporosis in a pre-menopausal woman. Best Pract Res Clin Rheumatol 24(3):313\u2013327. https:\/\/doi.org\/10.1016\/j.berh.2010.01.006","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"7336_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13697137.2021.1926974","volume":"25","author":"M Conradie","year":"2022","unstructured":"Conradie M, de Villiers T (2022) Premenopausal osteoporosis. Climacteric 25(1):73\u201380. https:\/\/doi.org\/10.1080\/13697137.2021.1926974","journal-title":"Climacteric"},{"issue":"5","key":"7336_CR7","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1210\/jc.2013-1172","volume":"98","author":"A Cohen","year":"2013","unstructured":"Cohen A, Stein EM, Recker RR et al (2013) Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab 98(5):1971\u20131981. https:\/\/doi.org\/10.1210\/jc.2013-1172","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7336_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12018-019-09262-2","volume":"17","author":"N Hong","year":"2019","unstructured":"Hong N, Rhee Y (2019) Comparison of efficacy of pharmacologic treatments in pregnancy- and lactation-associated osteoporosis. Clin Rev Bone Mineral Metab 17(2):86\u201393. https:\/\/doi.org\/10.1007\/s12018-019-09262-2","journal-title":"Clin Rev Bone Mineral Metab"},{"issue":"20","key":"7336_CR9","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Mar\u00edn F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357(20):2028\u20132039. https:\/\/doi.org\/10.1056\/NEJMoa071408","journal-title":"N Engl J Med"},{"issue":"5","key":"7336_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/s0020-1383(03)00117-7","volume":"35","author":"PW Thompson","year":"2004","unstructured":"Thompson PW, Taylor J, Dawson A (2004) The annual incidence and seasonal variation of fractures of the distal radius in men and women over 25 years in Dorset UK. Injury 35(5):462\u2013466. https:\/\/doi.org\/10.1016\/s0020-1383(03)00117-7","journal-title":"Injury"},{"issue":"5","key":"7336_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"issue":"1","key":"7336_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"issue":"16","key":"7336_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"15","key":"7336_CR14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"9","key":"7336_CR15","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183\u20133193. https:\/\/doi.org\/10.1210\/jc.2017-02163","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"7336_CR16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/mr\/roac059","volume":"33","author":"T Mochizuki","year":"2023","unstructured":"Mochizuki T, Yano K, Ikari K, Hiroshima R, Okazaki K (2023) Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: a randomized clinical pilot study. Mod Rheumatol 33(3):490\u2013495. https:\/\/doi.org\/10.1093\/mr\/roac059","journal-title":"Mod Rheumatol"},{"issue":"1","key":"7336_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/mrcr\/rxab018","volume":"6","author":"M Uehara","year":"2021","unstructured":"Uehara M, Nakamura Y, Nakano M, Miyazaki A, Suzuki T, Takahashi J (2021) Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: a case report. Modern Rheumatol Case Reports 6(1):128\u2013133. https:\/\/doi.org\/10.1093\/mrcr\/rxab018","journal-title":"Modern Rheumatol Case Reports"},{"issue":"5","key":"7336_CR18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00198-023-06668-z","volume":"34","author":"KJ Kim","year":"2023","unstructured":"Kim KJ, Hong N, Lee S, Shin S, Rhee Y (2023) Exploratory use of romosozumab for osteoporosis in a patient with Hajdu-Cheney syndrome: a case report. Osteoporos Int 34(5):1005\u20131009. https:\/\/doi.org\/10.1007\/s00198-023-06668-z","journal-title":"Osteoporos Int"},{"issue":"1","key":"7336_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/medicina59010019","volume":"59","author":"Y Kaneuchi","year":"2023","unstructured":"Kaneuchi Y, Iwabuchi M, Hakozaki M, Yamada H, Konno S-i (2023) Pregnancy and lactation-associated osteoporosis successfully treated with romosozumab: a case report. Medicina 59(1):19","journal-title":"Medicina"},{"key":"7336_CR20","doi-asserted-by":"publisher","unstructured":"Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, Rosen HN, Weber DR, Zemel BS, Shepherd JA (2019) Executive summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom 22(4):453\u2013471. https:\/\/doi.org\/10.1016\/j.jocd.2019.07.001","DOI":"10.1016\/j.jocd.2019.07.001"},{"issue":"1","key":"7336_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00198-011-1560-y","volume":"23","author":"A Cohen","year":"2012","unstructured":"Cohen A, Recker RR, Lappe J et al (2012) Premenopausal women with idiopathic low-trauma fractures and\/or low bone mineral density. Osteoporos Int 23(1):171\u2013182. https:\/\/doi.org\/10.1007\/s00198-011-1560-y","journal-title":"Osteoporos Int"},{"key":"7336_CR22","doi-asserted-by":"publisher","unstructured":"Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102(2):274\u2013282. https:\/\/doi.org\/10.1172\/jci2799","DOI":"10.1172\/jci2799"},{"issue":"3","key":"7336_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/(sici)1097-4644(20000301)76:3<518::aid-jcb18>3.0.co;2-m","volume":"76","author":"XM Shi","year":"2000","unstructured":"Shi XM, Blair HC, Yang X, McDonald JM, Cao X (2000) Tandem repeat of C\/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem 76(3):518\u2013527. https:\/\/doi.org\/10.1002\/(sici)1097-4644(20000301)76:3%3c518::aid-jcb18%3e3.0.co;2-m","journal-title":"J Cell Biochem"},{"issue":"10","key":"7336_CR24","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/jbmr.120","volume":"25","author":"I C\u00e1rcamo-Orive","year":"2010","unstructured":"C\u00e1rcamo-Orive I, Gaztelumendi A, Delgado J, Tejados N, Dorronsoro A, Fern\u00e1ndez-Rueda J, Pennington DJ, Trigueros C (2010) Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk. J Bone Miner Res 25(10):2115\u20132125. https:\/\/doi.org\/10.1002\/jbmr.120","journal-title":"J Bone Miner Res"},{"issue":"6","key":"7336_CR25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s00223-009-9303-1","volume":"85","author":"W Mak","year":"2009","unstructured":"Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H (2009) Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int 85(6):538\u2013545. https:\/\/doi.org\/10.1007\/s00223-009-9303-1","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"7336_CR26","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","volume":"140","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140(10):4382\u20134389. https:\/\/doi.org\/10.1210\/endo.140.10.7034","journal-title":"Endocrinology"},{"issue":"1","key":"7336_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jcb.21414","volume":"103","author":"T Kondo","year":"2008","unstructured":"Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S (2008) Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 103(1):335\u2013345. https:\/\/doi.org\/10.1002\/jcb.21414","journal-title":"J Cell Biochem"},{"issue":"1","key":"7336_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s2213-8587(13)70045-7","volume":"1","author":"MJ Seibel","year":"2013","unstructured":"Seibel MJ, Cooper MS, Zhou H (2013) Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 1(1):59\u201370. https:\/\/doi.org\/10.1016\/s2213-8587(13)70045-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"7336_CR29","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1210\/jc.2004-2042","volume":"90","author":"MA Donovan","year":"2005","unstructured":"Donovan MA, Dempster D, Zhou H, McMahon DJ, Fleischer J, Shane E (2005) Low bone formation in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 90(6):3331\u20133336. https:\/\/doi.org\/10.1210\/jc.2004-2042","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"7336_CR30","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1210\/jc.2011-1387","volume":"96","author":"A Cohen","year":"2011","unstructured":"Cohen A, Dempster DW, Recker RR et al (2011) Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 96(10):3095\u20133105. https:\/\/doi.org\/10.1210\/jc.2011-1387","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"7336_CR31","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/jbmr.3750","volume":"34","author":"A Cohen","year":"2019","unstructured":"Cohen A, Kamanda-Kosseh M, Dempster DW et al (2019) Women with pregnancy and lactation-associated osteoporosis (PLO) have low bone remodeling rates at the tissue level. J Bone Miner Res 34(9):1552\u20131561. https:\/\/doi.org\/10.1002\/jbmr.3750","journal-title":"J Bone Miner Res"},{"issue":"8","key":"7336_CR32","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH et al (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37(8):1437\u20131445. https:\/\/doi.org\/10.1002\/jbmr.4563","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7336_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/mr\/roac014","volume":"33","author":"T Kobayakawa","year":"2023","unstructured":"Kobayakawa T, Miyazaki A, Kanayama Y, Hirano Y, Takahashi J, Suzuki T, Nakamura Y (2023) Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol 33(1):96\u2013103. https:\/\/doi.org\/10.1093\/mr\/roac014","journal-title":"Mod Rheumatol"},{"issue":"4","key":"7336_CR34","doi-asserted-by":"publisher","first-page":"e1528","DOI":"10.1210\/clinem\/dgab850","volume":"107","author":"E Shane","year":"2022","unstructured":"Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A (2022) Denosumab after teriparatide in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 107(4):e1528\u2013e1540. https:\/\/doi.org\/10.1210\/clinem\/dgab850","journal-title":"J Clin Endocrinol Metab"},{"key":"7336_CR35","doi-asserted-by":"publisher","unstructured":"McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Shi Y, Timoshanko J, Libanati C, Chines A, Oates MK (2021) Skeletal responses to romosozumab after 12 months of denosumab. JBMR Plus 5(7). https:\/\/doi.org\/10.1002\/jbm4.10512","DOI":"10.1002\/jbm4.10512"},{"issue":"6","key":"7336_CR36","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, Rojeski M, McDermott M, Oates MK, Milmont CE (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33(6):1243\u20131256","journal-title":"Osteoporos Int"},{"issue":"1","key":"7336_CR37","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bone.2013.07.040","volume":"57","author":"K Briot","year":"2013","unstructured":"Briot K, Paternotte S, Kolta S, Eastell R, Reid DM, Felsenberg D, Gl\u00fcer CC, Roux C (2013) Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: The OPUS study. Bone 57(1):232\u2013236. https:\/\/doi.org\/10.1016\/j.bone.2013.07.040","journal-title":"Bone"},{"key":"7336_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bone.2015.06.007","volume":"79","author":"C Muschitz","year":"2015","unstructured":"Muschitz C, Kocijan R, Haschka J, Pahr D, Kaider A, Pietschmann P, Hans D, Muschitz GK, Fahrleitner-Pammer A, Resch H (2015) TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone 79:259\u2013266. https:\/\/doi.org\/10.1016\/j.bone.2015.06.007","journal-title":"Bone"},{"key":"7336_CR39","doi-asserted-by":"publisher","unstructured":"Jeong C, Kim J, Lim Y, Ha J, Kang MI, Baek KH (2021) Effect of romosozumab on trabecular bone score compared to anti-resorptive agents in postmenopausal women with osteoporosis. J Bone Metab 28(4):317\u2013323. https:\/\/doi.org\/10.11005\/jbm.2021.28.4.317","DOI":"10.11005\/jbm.2021.28.4.317"},{"issue":"9","key":"7336_CR40","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jbmr.3735","volume":"34","author":"P Chavassieux","year":"2019","unstructured":"Chavassieux P, Chapurlat R, Portero-Muzy N, Roux J-P, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A (2019) Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res 34(9):1597\u20131608. https:\/\/doi.org\/10.1002\/jbmr.3735","journal-title":"J Bone Miner Res"},{"issue":"12","key":"7336_CR41","doi-asserted-by":"publisher","first-page":"e82436","DOI":"10.1371\/journal.pone.0082436","volume":"8","author":"Y Gao","year":"2013","unstructured":"Gao Y, Huang E, Zhang H et al (2013) Crosstalk between Wnt\/\u03b2-catenin and estrogen receptor signaling synergistically promotes osteogenic differentiation of mesenchymal progenitor cells. PLoS ONE 8(12):e82436. https:\/\/doi.org\/10.1371\/journal.pone.0082436","journal-title":"PLoS ONE"},{"issue":"2","key":"7336_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","volume":"19","author":"EM Lewiecki","year":"2016","unstructured":"Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ, Gordon CM, Jankowski LG, Lee J-K, Leslie WD (2016) Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom 19(2):127\u2013140","journal-title":"J Clin Densitom"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07336-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07336-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:57:24Z","timestamp":1739440644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07336-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7336"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07336-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Seunghyun Lee, Namki Hong, Sung Joon Cho, and Sungjae Shin declare that this study was conducted without commercial or financial relationships that could be construed as potential conflicts of interest. Yumie Rhee has been an investigator for Amgen, Kyowa Kirin, Sanofi, Daewoong, Alexion, and Donga ST and a speaker for Amgen, Kyowa Kirin.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}